The global breast cancer therapeutics market was valued at $17.4 Billion in 2017 and is forecast to grow at a modest XX.2 % CAGR between 2018 and 2025, culminating in 2025 global sales of $35.5 Billion.
As per WHO, 508 000 women worldwide died due to breast cancer in 2011 (Global Health Estimates, WHO 2013) and the trend keep rising. Although it is considered a disease of the developed world, almost 50% of breast cancer cases and 58% of deaths occur in less developed countries (GLOBOCAN 2008). Due to recent development in therapeutic and radiation therapy, survival rates ranging from 80% or over in North America, Sweden, and Japan to around 60% in middle-income countries and below 40% in low-income countries
Long exposure to endogenous estrogens, such as early menarche, late menopause, late age at first childbirth is among the most important risk factors for breast cancer. Exogenous hormones, oral contraceptive, and hormone replacement therapy put patients at higher risk for breast cancer. Breastfeeding has a protective effect.
Check Out for Full Report Global Breast Cancer Therapeutics Market Research Report
No comments:
Post a Comment